251 related articles for article (PubMed ID: 38455044)
1. Research progress of Ustekinumab in the treatment of inflammatory bowel disease.
Zhang W; Zhong G; Ren X; Li M
Front Immunol; 2024; 15():1322054. PubMed ID: 38455044
[TBL] [Abstract][Full Text] [Related]
2. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB).
Romero RK; Magro DO; Queiroz NSF; Damião AOMC; Teixeira FV; Nones RB; Sassaki LY; Saad-Hossne R; Kotze PG
Gastroenterol Hepatol; 2022; 45(7):499-506. PubMed ID: 34634427
[TBL] [Abstract][Full Text] [Related]
3. Real-World Persistence of Ustekinumab in the Treatment of Inflammatory Bowel Disease.
Bressler B; Jones J; In TSH; Lan T; Iconaru C; Marshall JK
Adv Ther; 2023 Oct; 40(10):4421-4439. PubMed ID: 37507652
[TBL] [Abstract][Full Text] [Related]
4. Targeting IL-23 for IBD: Rationale and Progress to Date.
Vuyyuru SK; Shackelton LM; Hanzel J; Ma C; Jairath V; Feagan BG
Drugs; 2023 Jul; 83(10):873-891. PubMed ID: 37266801
[TBL] [Abstract][Full Text] [Related]
5. Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block.
Fiorino G; Allocca M; Correale C; Roda G; Furfaro F; Loy L; Zilli A; Peyrin-Biroulet L; Danese S
Expert Opin Biol Ther; 2020 Apr; 20(4):421-427. PubMed ID: 32027523
[No Abstract] [Full Text] [Related]
6. Anti-IL-12/23p40 antibodies for maintenance of remission in Crohn's disease.
Davies SC; Nguyen TM; Parker CE; MacDonald JK; Jairath V; Khanna R
Cochrane Database Syst Rev; 2019 Dec; 12(12):CD012804. PubMed ID: 31828765
[TBL] [Abstract][Full Text] [Related]
7. Blockade of IL-23: What is in the Pipeline?
Parigi TL; Iacucci M; Ghosh S
J Crohns Colitis; 2022 May; 16(Supplement_2):ii64-ii72. PubMed ID: 35553666
[TBL] [Abstract][Full Text] [Related]
8. Role of ustekinumab in treatment of ulcerative colitis: a narrative review.
Grova M; Vitello A; Mannino M; Casà A; Renna S; Macaluso FS; Orlando A
Immunotherapy; 2023 Dec; 15(18):1539-1552. PubMed ID: 38018475
[TBL] [Abstract][Full Text] [Related]
9. A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases.
Verstockt B; Deleenheer B; Van Assche G; Vermeire S; Ferrante M
Expert Opin Drug Saf; 2017 Jul; 16(7):809-821. PubMed ID: 28573876
[TBL] [Abstract][Full Text] [Related]
10. Higher Ustekinumab Levels in Maintenance Therapy are Associated with Greater Mucosal Healing and Mucosal Response in Crohn's Disease: An Experience of 2 IBD Centers.
McDonald C; Kerr H; Gibbons E; Lukose T; Cheriyan D; Harewood G; Patchett S; O'Toole A; Kelly O; Boland K
Inflamm Bowel Dis; 2024 Mar; 30(3):423-428. PubMed ID: 37158577
[TBL] [Abstract][Full Text] [Related]
11. Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction.
Proietti E; Pauwels RWM; van der Woude CJ; Doukas M; Oudijk L; Peppelenbosch MP; Grohmann U; Crombag MBS; de Vries AC; Fuhler GM
Inflamm Bowel Dis; 2023 Jul; 29(7):1038-1046. PubMed ID: 35917118
[TBL] [Abstract][Full Text] [Related]
12. Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease.
Almradi A; Hanzel J; Sedano R; Parker CE; Feagan BG; Ma C; Jairath V
BioDrugs; 2020 Dec; 34(6):713-721. PubMed ID: 33105016
[TBL] [Abstract][Full Text] [Related]
13. An update on the role of anti-IL-12/IL23 agents in the management of inflammatory bowel disease.
Nigam GB; Limdi JK
Br Med Bull; 2021 Jun; 138(1):29-40. PubMed ID: 33884410
[TBL] [Abstract][Full Text] [Related]
14. Review article: predictors of response to vedolizumab and ustekinumab in inflammatory bowel disease.
Barré A; Colombel JF; Ungaro R
Aliment Pharmacol Ther; 2018 Apr; 47(7):896-905. PubMed ID: 29430672
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive Review of Ustekinumab Utilization in Inflammatory Bowel Diseases: Insights from the ClinicalTrials.gov Registry.
Alorfi NM; Alourfi MM; Bokhari GA; Alkhattabi A; Ibrahim NA; Alsabban AM; Almatrafi MJ; Zakri YA; Almahmoud AJ; Al-Ghamdi KMA; Alsharif SN
Int J Gen Med; 2023; 16():4283-4294. PubMed ID: 37750106
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of Ustekinumab for Treating a Case of Myelodysplastic Syndrome-associated Inflammatory Bowel Disease.
Kono M; Sakurai T; Okamoto K; Nagai T; Komeda Y; Kashida H; Minaga K; Kamata K; Takenaka M; Hagiwara S; Watanabe T; Nishida N; Enoki E; Inoue H; Matsumura I; Kudo M
Intern Med; 2019 Jul; 58(14):2029-2033. PubMed ID: 30996178
[TBL] [Abstract][Full Text] [Related]
17. Treatment persistence of ustekinumab and vedolizumab in IBD patients is independent of prior immunogenicity to anti-TNFs: a retrospective study.
Blesl A; Petritsch W; Binder L; Fürst S; Wenzl H; Baumann-Durchschein F; Kump P; Högenauer C
Scand J Gastroenterol; 2022 Nov; 57(11):1327-1330. PubMed ID: 35732583
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-23 Blockers: Born to be First-line Biologic Agents in Inflammatory Bowel Disease?
Argollo MC; Allocca M; Furfaro F; Peyrin-Biroulet L; Danese S
Curr Pharm Des; 2019; 25(1):25-31. PubMed ID: 31092171
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic drug monitoring in patients with inflammatory bowel disease on ustekinumab.
Saleh A; Stading R; Miroballi N; Glassner K; Abraham BP
J Dig Dis; 2024 Apr; 25(4):214-221. PubMed ID: 38587053
[TBL] [Abstract][Full Text] [Related]
20. Anti-IL-12/23p40 antibodies for induction of remission in Crohn's disease.
MacDonald JK; Nguyen TM; Khanna R; Timmer A
Cochrane Database Syst Rev; 2016 Nov; 11(11):CD007572. PubMed ID: 27885650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]